MedChemBench, OpenAI's medicinal chemistry benchmark, is drawn from 117 papers and patents covering 761 graded molecular structures, with each prompt stopping at a real decision point and providing the biological target, prior compounds, and selected assay results. The benchmark withholds results that researchers reported later, testing genuine predictive ability. GPT-6.2 Astra is the top-performing model at roughly 84% overall accuracy, described as near-perfect at reading chemistry but correct only about half the time on the decision that actually matters.
OpenAI has released a series of Rosalind-branded models alongside the benchmark. GPT-Rosalind-5.5, designed specifically for medicinal chemistry, scores 27.5% on MedChemBench versus GPT-5.5's 25.1% while using 7.2% fewer tokens. GPT-6 Rosalind, priced at $15/$75 per million tokens, raised MedChemBench v7 scores from 28.9% to 49.6% at the highest reasoning budget compared to GPT-Rosalind-5.5, improved GeneBench Pro v13 scores from 16.7% to 37.7%, and raised LifeSciBench Gold scores from 44.0% to 61.3%, while also increasing the refusal rate on a biorisk safety test. LLM Stats tracks four OpenAI models on MedChemBench; GPT-5.6 Sol leads that leaderboard at 0.483 on a 0-to-1 scale, with the field average at 0.4.
OpenAI also developed LifeSciBench, an externally expert-judged benchmark covering six workflow areas in life sciences research, described as taking an end-to-end view of scientifically valuable work rather than evaluating single components in isolation.
In a separate application, GPT-Rosalind working with Perturb-AI and Scripps Research analyzed gene-expression data from millions of mouse brain cells in 32 minutes and surfaced a hypothesis that disrupted cholesterol transport may drive neurodegeneration linked to the DCTN1 gene, which is associated with Perry syndrome. That collaboration is described as expanding to identify new drug targets for neurodegenerative diseases.